A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209
Open Access
- 17 January 2018
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (8) , 8155-8164
Abstract
A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209 A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209Keywords
This publication has 24 references indexed in Scilit:
- Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune primingMolecular Cancer, 2011
- Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor ImmunityMolecular Cancer Therapeutics, 2010
- PD-1, gender, and autoimmunityAutoimmunity Reviews, 2010
- Oncolytic Viral Therapy for Prostate Cancer: Efficacy of Reovirus as a Biological TherapeuticCancer Research, 2010
- Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cellsMolecular Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Reovirus Core Protein μ2 Determines the Filamentous Morphology of Viral Inclusion Bodies by Interacting with and Stabilizing MicrotubulesJournal of Virology, 2002
- Reovirus Oncolysis of Human Breast CancerHuman Gene Therapy, 2002